These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

891 related items for PubMed ID: 11535168

  • 1. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA, Gallo-Penn A, Andrews J, Idamakanti N, Kaleko M, Connelly S.
    Hum Gene Ther; 2001 Sep 01; 12(13):1651-61. PubMed ID: 11535168
    [Abstract] [Full Text] [Related]

  • 2. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE, Shi CX, Brown B, McKinven A, Tinlin S, Graham FL, Hough C, Lillicrap D.
    J Gene Med; 2004 Dec 01; 6(12):1358-68. PubMed ID: 15493040
    [Abstract] [Full Text] [Related]

  • 3. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
    Sarkar R, Gao GP, Chirmule N, Tazelaar J, Kazazian HH.
    Hum Gene Ther; 2000 Apr 10; 11(6):881-94. PubMed ID: 10779165
    [Abstract] [Full Text] [Related]

  • 4. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
    Andrews JL, Kadan MJ, Gorziglia MI, Kaleko M, Connelly S.
    Mol Ther; 2001 Mar 10; 3(3):329-36. PubMed ID: 11273775
    [Abstract] [Full Text] [Related]

  • 5. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.
    Gallo-Penn AM, Shirley PS, Andrews JL, Kayda DB, Pinkstaff AM, Kaloss M, Tinlin S, Cameron C, Notley C, Hough C, Lillicrap D, Kaleko M, Connelly S.
    Hum Gene Ther; 1999 Jul 20; 10(11):1791-802. PubMed ID: 10446919
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillicrap D, Collen D, VandenDriessche T, Kochanek S.
    Blood; 2003 Mar 01; 101(5):1734-43. PubMed ID: 12406898
    [Abstract] [Full Text] [Related]

  • 7. In vivo dose threshold effect of adenovirus-mediated factor VIII gene therapy in hemophiliac mice.
    Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S.
    Mol Ther; 2000 Sep 01; 2(3):223-32. PubMed ID: 10985953
    [Abstract] [Full Text] [Related]

  • 8. Sustained human factor VIII expression in hemophilia A mice following systemic delivery of a gutless adenoviral vector.
    Reddy PS, Sakhuja K, Ganesh S, Yang L, Kayda D, Brann T, Pattison S, Golightly D, Idamakanti N, Pinkstaff A, Kaloss M, Barjot C, Chamberlain JS, Kaleko M, Connelly S.
    Mol Ther; 2002 Jan 01; 5(1):63-73. PubMed ID: 11786047
    [Abstract] [Full Text] [Related]

  • 9. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.
    Balagué C, Zhou J, Dai Y, Alemany R, Josephs SF, Andreason G, Hariharan M, Sethi E, Prokopenko E, Jan HY, Lou YC, Hubert-Leslie D, Ruiz L, Zhang WW.
    Blood; 2000 Feb 01; 95(3):820-8. PubMed ID: 10648392
    [Abstract] [Full Text] [Related]

  • 10. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q.
    J Thromb Haemost; 2012 Aug 01; 10(8):1570-80. PubMed ID: 22632092
    [Abstract] [Full Text] [Related]

  • 11. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, Herzog RW.
    PLoS One; 2012 Aug 01; 7(5):e37671. PubMed ID: 22655063
    [Abstract] [Full Text] [Related]

  • 12. The humoral response to human factor VIII in hemophilia A mice.
    Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P.
    J Thromb Haemost; 2007 Mar 01; 5(3):512-9. PubMed ID: 17181826
    [Abstract] [Full Text] [Related]

  • 13. Identification of a novel immunodominant cytotoxic T lymphocyte epitope derived from human factor VIII in a murine model of hemophilia A.
    Wang W, Merchlinsky M, Inman J, Golding B.
    Thromb Res; 2005 Mar 01; 116(4):335-44. PubMed ID: 16038719
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB, Gangadharan B, Dukart HZ, Spencer HT.
    Mol Ther; 2007 Jun 01; 15(6):1093-9. PubMed ID: 17387335
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High-level tissue-specific expression of functional human factor VIII in mice.
    Connelly S, Gardner JM, McClelland A, Kaleko M.
    Hum Gene Ther; 1996 Jan 20; 7(2):183-95. PubMed ID: 8788169
    [Abstract] [Full Text] [Related]

  • 19. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M, Palaschak B, Kumar SRP, Rana J, Markusic DM.
    Front Immunol; 2020 Jan 20; 11():1293. PubMed ID: 32670285
    [Abstract] [Full Text] [Related]

  • 20. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A, Mimuro J, Kashiwakura Y, Niimura M, Takano K, Ohmori T, Madoiwa S, Mizukami H, Okada T, Naka H, Yoshioka A, Ozawa K, Sakata Y.
    Thromb Res; 2006 Jan 20; 118(5):627-35. PubMed ID: 16371232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.